News coverage about Nightstar Therapeutics (NASDAQ:NITE) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nightstar Therapeutics earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.5782211332997 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several equities research analysts have issued reports on NITE shares. Chardan Capital started coverage on Nightstar Therapeutics in a report on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 price target for the company. Jefferies Group started coverage on Nightstar Therapeutics in a report on Monday, October 23rd. They issued a “buy” rating and a $25.00 price target for the company. Wedbush restated an “outperform” rating and issued a $31.00 price target (up from $29.00) on shares of Nightstar Therapeutics in a report on Wednesday, January 17th. Leerink Swann started coverage on Nightstar Therapeutics in a report on Monday, October 23rd. They issued an “outperform” rating and a $25.00 price target for the company. Finally, BMO Capital Markets started coverage on Nightstar Therapeutics in a report on Monday, October 23rd. They issued an “outperform” rating and a $30.00 price target for the company. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $30.20.
Shares of Nightstar Therapeutics (NASDAQ NITE) traded down $0.89 during trading on Friday, hitting $10.41. The company’s stock had a trading volume of 56,700 shares, compared to its average volume of 29,119. Nightstar Therapeutics has a 12 month low of $10.20 and a 12 month high of $24.93.
ILLEGAL ACTIVITY NOTICE: “Nightstar Therapeutics (NITE) Given Daily Media Impact Score of 0.05” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/16/nightstar-therapeutics-nite-given-daily-media-impact-score-of-0-05.html.
About Nightstar Therapeutics
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.